Car-nk cell therapy for relapsed b-cell leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment using your own immune cells (called CAR-NK cells) that are trained to find and kill leukemia cells. It may be an option if your B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 3 years or older and have B-ALL that is CD19 positive (a protein on the cancer cells).
- Your overall health should be good enough for treatment, as measured by your daily activity level (ECOG score 0–2 or Karnofsky score above 60).
- You need adequate blood cell counts and liver/kidney function, checked within the past week.
- If you are a woman able to have children, you must have a negative pregnancy test and agree to use birth control for up to two weeks after the last infusion.
- You cannot have serious infections like HIV, hepatitis B or C, or other uncontrolled medical conditions.
- You cannot have had certain chemotherapy drugs (fludarabine or cladribine) in the 3 months before the cell collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Hear when a new Acute Lymphocytic Leukemia in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.